INTRODUCTION
============

Endoscopic ultrasound-guided fine-needle aspiration (EUSFNA) has become a standard method for the pathological diagnosis of upper abdominal lesions, such as pancreatic tumors, gastrointestinal submucosal tumors, or the lymph nodes \[[@b1-ce-2019-081]-[@b6-ce-2019-081]\].

The usefulness of EUS-FNA for lower abdominal lesions is questionable, with only a few supporting evidence-based studies. Recently, the use of EUS-FNA for the lower abdomen has gained popularity with the use of curved linear-array echoendoscopy-EUS (CLA-EUS) \[[@b7-ce-2019-081]-[@b12-ce-2019-081]\]. Most trials puncture mainly in the rectal and perirectal area because of the technical difficulty and risk of perforation for deeper insertion. However, proximal colonic insertion can be easily performed, such as conventional colonoscopy using forward-viewing therapeutic linear echoendoscopy-EUS (FV-EUS), which combines the front endoscopic and ultrasonographic views. However, FNA of extracolonic lesions is still a technical challenge.

In this study, we report our experience with transcolonic EUS-FNA for extracolonic lesions in the lower abdominopelvic cavity using FV-EUS under fluoroscopic guidance.

MATERIAL AND METHODS
====================

Patients
--------

A retrospective review of 13 consecutive patients who underwent transcolonic EUS-FNA with FV-EUS under fluoroscopic guidance at the Aichi Cancer Center Hospital, Nagoya, Japan from June 2015 to November 2018 was conducted. All patient had an intra-abdominopelvic mass or abnormal lymph node detected on cross-sectional imaging, such as abdominopelvic computed tomography (CT), magnetic resonance imaging (MRI), or positron emission tomography/CT (PET/ CT). All patients provided informed consent for EUS-FNA. The study protocol was approved by the Institutional Review Board (IRB No. 2018-1-223 date 5/Nov/2018).

EUS-FNA technique
-----------------

A forward-view echoendoscope (TGF-UC260J; Olympus Medical Systems, Tokyo, Japan) was used for all patients. Compared to CLA-EUS, FV-EUS has unique advantages, such as of a straight channel port, wider bending angulation, and shorter distal end ([Fig. 1](#f1-ce-2019-081){ref-type="fig"}) These features provide greater puncture force and ability to access the proximal colon. The disadvantage of FV-EUS is a narrower ultrasonographic scanning range (90⁰) compared to that of the CLA-EUS (180⁰). We added an extra monitor for the cross-sectional imaging in addition to the fluoroscopic monitor to compare the scope position relative to the target lesion.

The procedure was performed under conscious sedation with intravenous administration of midazolam and pethidine. First, the patient was placed in the left lateral position. The FV-EUS scope was inserted under the endoscopic view into the colonic segment near the target FNA lesion. A C-arm X-ray machine was used to change the plane of the X-ray and compare the scope tip position on fluoroscopy to the target FNA lesion on cross-sectional imaging, such as CT, MRI, or PET/CT ([Fig. 2](#f2-ce-2019-081){ref-type="fig"}). Next, the target lesion was searched under the ultrasonographic view. When the target lesion was found, fluoroscopy was used to confirm that the position and direction of the scope was correct and close to the target lesion, as on cross-sectional imaging ([Fig. 2](#f2-ce-2019-081){ref-type="fig"}).

FNA was performed with a 22- or 25-gauge needle. After each puncture, specimens were sent for rapid onsite evaluation (ROSE), cytology, and/or tissue cell block. FNA was repeated, varying from one to six times, depending on the ROSE result. All procedures were performed in the fluoroscopic room by four experienced endosonographers at our center.

Outcomes
--------

The primary outcome of this study was the diagnostic ability of EUS-FNA. The diagnosis was made using cytology and/ or cell block. The outcome was evaluated based on sensitivity, specificity, and accuracy for the diagnosis. [Table 1](#t1-ce-2019-081){ref-type="table"} presents the other outcomes, including location and size of the lesion, puncture site, provisional diagnosis, procedure time, cytological outcome, final diagnosis, and adverse events.

RESULTS
=======

From June 2015 to November 2018, EUS-FNA was performed at our center with FV-EUS under fluoroscopic guidance for 13 patients with extracolonic lesions. The sensitivity, specificity, and accuracy of EUS-FNA for detecting malignant lesions in this study were 91%, 100%, and 92%, respectively. There was only one false-negative case, which was of a chemotherapy patient after rectal cancer surgery. [Table 1](#t1-ce-2019-081){ref-type="table"} summarizes the clinical, radiological, and procedural data.

Most patients (69%) had undergone surgery for colorectal cancer with suspected recurrence on follow-up imaging (typically CT, MRI, or PET/CT) and showed an intraabdominal lymph node or mass. The median diameter of the target FNA lesion was 20 mm, with an interquartile range (IQR) of 18--33.5 mm, and the most common puncture location was the lower intra-abdominopelvic cavity by the transigmoid or transrectal FNA. The FNA procedure can be performed successfully in patients (100% technical success) with a median procedural time of 31 min with an IQR of 21--46 min. There were no adverse events associated with the EUS-FNA procedure.

DISCUSSION
==========

Recent studies showed that CLA-EUS is effective and safe for FNA of perirectal lesions \[[@b12-ce-2019-081]-[@b14-ce-2019-081]\]. However, for proximal pericolonic lesions, CLA-EUS seems to be technically difficult in scope insertion and increases the risk of perforation. To our knowledge, there is only one study that used CLA-EUS for FNA. In that study by Sasaki et al. \[[@b15-ce-2019-081]\], FNA was performed for the colonic submucosal mass and extrinsic masses abutting to the wall of the colon proximal to the sigmoid colon in four patients, using CLA-EUS together with the overtube and guidewire. First, they used a colonoscope to insert the overtube and guidewire, and subsequently, inserted the CLA-EUS scope into the overtube under the guidewire. However, this technique is complicated, time-consuming, and requires many instruments.

To overcome these limitations, our institution used FV-EUS in combination with fluoroscopic guidance as the first-line technique to perform FNA for intra-abdominal and pelvic cavity lesions. The FV-EUS scope can be easily navigated and inserted into the proximal colon like a conventional colonoscope. To our knowledge, there are only two published studies using FV-EUS for FNA of the pericolonic lesion; however, neither study used fluoroscopy. In the first study, by Nguyen-Tang et al. \[[@b16-ce-2019-081]\] in 2010, FV-EUS was performed to evaluate and obtain samples of the right-sided colonic subepithelial lesions in 15 patients. With FV-EUS, they could reach the cecum within 10 minutes in every case. This study confirmed that FV-EUS can provide easy and safe insertion into the proximal colon. However, all target lesions in this study were subepithelial lesions that could be found under the conventional endoscopic view. The second study, by Uchida et al. \[[@b17-ce-2019-081]\] in 2010, reported using FV-EUS for FNA of extracolonic lesions in two patients. The target lesions were 30 mm of the common iliac lymph node abutting to the ascending colon and a 7-cm mass surrounding the descending colon. These two studies suggested that FV-EUS is effective and safe for FNA of proximal pericolonic lesions.

However, while using FV-EUS without fluoroscopy, it is difficult to find the target lesion under the ultrasonographic view alone because the scanning range of the FV-EUS (90⁰) is narrower than that of the CLA-EUS (180⁰). In addition, there is no standard homebase structure in the proximal colon. Therefore, without fluoroscopic guidance, FNA would be suitable for subepithelial lesions (visible in the endoscopic view) or big lesions that are easily seen under the ultrasound view, as in previous studies. However, FNA of small extracolonic lesions are still challenging with FV-EUS. Our center uses fluoroscopy to aid FV-EUS in finding the target lesion by positioning the tip of the scope as close as possible to the target lesion on cross-sectional imaging before scanning and puncture ([Fig. 2](#f2-ce-2019-081){ref-type="fig"}). In our results, the target lesions were small, with a median diameter of 20 mm (IQR, 17.2 mm), and the median procedure time was 31 min (IQR, 26 min). We believe that this technique can facilitate in locating the target lesions (even small extracolonic lesions) on ultrasound. Moreover, tissue sampling for histopathologic examination was technically successful in all patients, with a sensitivity of 91% and specificity of 100%, which allowed to differentiate between neoplastic and non-neoplastic lesions without any post-procedural adverse events. These outcomes showed that the effectiveness and safety of this technique were acceptable and comparable to those of standard EUS-FNA.

In our study, most lesions were located in the lower abdominopelvic cavity on EUS-FNA in the distal colon, while five and six were in the rectum and sigmoid colon, respectively. Only two cases were punctured more proximal in the distal descending colon and cecum. The lesion in the upper abdominal cavity can be punctured using transoral EUS-FNA or ultrasound-guided percutaneous biopsy without difficulty. Transcolonic EUS-FNA is best indicated for FNA of lesions in the lower abdominopelvic cavity by puncturing through rectum, sigmoid, and distal descending colon because the lesion in this area is surrounded by pelvic bones and major organs, such as the urinary bladder and uterus, which make the percutaneous approach difficult. We also used FV-EUS as the first-line technique for FNA of perirectal lesions (5 cases). Our endoscopists reported that compared to the experience with CLA-EUS, FV-EUS with a short scope tip was easier for scope manipulation and puncture, especially for the lesions in the lower rectum with limited space. Moreover, EUS-FNA with FV-EUS under fluoroscopy does not require expertise in EUS, so this technique may be more helpful, particularly in centers where an expert endosonographer is not available.

Our study had several limitations. First, our study had a retrospective design in a single center with a few cases. Second, although this study reported using FV-EUS of proximal pericolonic lesions, all cases except one were of left-sided pericolonic lesions. Large prospective cohort studies are required to validate the findings of this study.

In conclusion, diagnosing lower intra-abdominopelvic lesions is still challenging. However, FV-EUS under fluoroscopic guidance is an easy, safe, and effective technique for transcolonic EUS-FNA of lesions in the abdominopelvic cavity.

**Conflicts of Interest:**

The authors have no financial conflicts of interest.

**Author Contributions**

Conceptualization: Nithi Thinrungroj, Kazuo Hara, Nobumasa Mizuno, Takamichi Kuwahara, Nozomi Okuno

Data curation: NT, NM, TK, NO

Formal analysis: NT, NM, TK, NO

Supervision: KH, NM, TK, NO

Writing-original draft: NT

Writing-review&editing: KH

![Forward-view echoendoscope (TGF-UC260J; Olympus Medical Systems, Tokyo, Japan) with a transparent cap.](ce-2019-081f1){#f1-ce-2019-081}

![The target lesion (green arrow) on positron emission tomography/computed tomography (PET/CT) (A), and the scope tip position on fluoroscopy (B) in patient 9. The target lesion (green arrow) on PET/CT (C), and the scope tip position on fluoroscopy (D) in patient 11. The target lesion (green arrow) on PET/CT (E), and the scope tip position on fluoroscopy (F) in patient 13.](ce-2019-081f2){#f2-ce-2019-081}

###### 

Clinical, Radiological, and Procedural Data

  Patient   Target lesion            Size (mm)   Imaging   Provisional diagnosis        Site of FNA        Procedure time (min)   Cytology and/or cell block   Final diagnosis                         Adverse event
  --------- ------------------------ ----------- --------- ---------------------------- ------------------ ---------------------- ---------------------------- --------------------------------------- ---------------
  1         Pelvic cavity LN         18          PET/CT    Recurrent rectal cancer      Sigmoid colon      50                     No malignancy                Recurrent rectal cancer                 No
  2         Appendiceal mass         33.5        PET/CT    Appendiceal Tumor            Sigmoid colon      48                     Granulation tissue           Mass forming appendicitis               No
  3         Pelvic cavity mass       43          PET/CT    Recurrent rectal cancer      Rectum             44                     Adenocarcinoma               Recurrent rectal cancer                 No
  4         peritoneal mass          28          PET/CT    Metastatic CCA               Rectum             31                     Adenocarcinoma               CCA, peritoneal metastasis              No
  5         Pelvic cavity LN         12.2        PET/CT    Recurrent colon cancer       Rectum             46                     Adenocarcinoma               Recurrent colon cancer                  No
  6         Pelvic cavity LN         15          PET/CT    Metastatic gastric cancer    Rectum             20                     Adenocarcinoma               Recurrent gastric cancer                No
  7         Pelvic cavity mass       40          CT        Recurrent ovar- ian cancer   Sigmoid colon      21                     Adenocarcinoma               Ovarian cancer, peritoneal metastasis   No
  8         Pelvic nodule            40          PET/CT    Recurrent rectal cancer      Rectum             19                     Adenocarcinoma               Recurrent rectal cancer                 No
  9         Retroperito- neal mass   18          PET/CT    Recurrent colon cancer       Sigmoid colon      48                     Adenocarcinoma               Recurrent colon cancer                  No
  10        Pelvic cavity LN         20          CT        Recurrent rectal cancer      Sigmoid colon      28                     No malignancy                Benign LN                               No
  11        Pelvic cavity LN         19.3        PET/CT    Recurrent colon cancer       Descending colon   31                     Adenocarcinoma               Recurrent colon cancer                  No
  12        Retroperito- neal LN     17.8        PET/CT    Recurrent rectal cancer      Sigmoid colon      13                     Adenocarcinoma               Recurrent rectal cancer                 No
  13        Pericecal nodule         20          PET/CT    Recurrent rectal cancer      Cecum              34                     Adenocarcinoma               Recurrent rectal cancer                 No

CCA, cholangiocarcinoma; CT, computed tomography; FNA, fine-needle aspiration; LN, lymph node; PET, positron emission tomography.
